Viewing nowPimamon Tablet 60 Milligrams (Pimasartan Potassium Trihydrate)
Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

MFDS item code 202402925 · Approved 2024.12.11 · Insurance code 653405860
Treatment of essential hypertension
This medication is used for essential hypertension, a prevalent type of hypertension.
Essential hypertension Adults The recommended dose of this medicine is 30 ~ 60 milligrams once daily, with or without food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take this medicine at the same time every day (e.g., in the morning). The blood pressure-lowering effect occurs within 2 weeks of starting treatment and reaches its maximum effect after approximately 8 weeks ~ 12 weeks. Elderly patients No initial dose adjustment is required in elderly patients aged 70 years or younger. For patients over 70 years of age, the recommended initial dose is 30 mg of this medicine once daily. (See section 9. Administration to elderly patients under Precautions for Use.) Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), start treatment with 30 milligrams once daily and do not exceed 60 milligrams per day. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, do not administer this medicine to patients with moderate to severe hepatic impairment (see sections 2. Patients who must not receive this medicine and 10. Administration to patients with hepatic impairment under Precautions for Use). Patients with reduced effective intravascular volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective intravascular volume, an initial dose of 30 milligrams once daily is recommended. (See section 3. Patients who require careful administration under Precautions for Use.)
The safety and efficacy of this medicine in pediatric and adolescent patients aged 18 years or younger have not been established.
This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, and must be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by individuals allergic to any of its components, pregnant women, or those who are breastfeeding. It is also contraindicated in patients with renal dialysis, moderate to severe liver impairment, or bile duct obstruction. Patients with diabetes or who are taking specific medications with moderate to severe renal function impairment should not take this medication. Patients with lactose intolerance or certain genetic metabolic disorders should not take this medication. Patients with low blood volume or sodium deficiency, impaired kidney function, or renal vascular hypertension require special precautions when taking this medication, and their condition must be closely monitored. Caution is also advised in patients with aortic stenosis, mitral valve stenosis, or obstructive heart disease. This medication contains Yellow No. 4 (Tartrazine), and patients sensitive to this ingredient should take it with caution. Common side effects include headaches and dizziness, while rare side effects may include dyspepsia, muscle stiffness, skin rashes, and blood pressure changes. Serious adverse reactions reported include acute renal failure, hepatitis, stroke, and heart failure; if any unusual symptoms occur during use, immediate consultation with a healthcare professional is advised. There is a risk of hypotension or electrolyte imbalance, so careful adjustment of dosage and monitoring of condition are essential, particularly when taken with diuretics or when blood volume is reduced. Regular monitoring of serum potassium levels is recommended during the course of treatment. Informing healthcare professionals of the medication's use is crucial during surgery or anesthesia to prevent hypotension. Caution is required when driving or operating machinery, as drowsiness or dizziness may occur. There may be interactions with other antihypertensives, potassium-sparing diuretics, lithium, and non-steroidal anti-inflammatory drugs, so any other medications being taken should be disclosed. Women who are pregnant or breastfeeding should avoid taking this medication and consult their physician regarding the necessity of taking it. Safety and efficacy in pediatric patients under 18 years of age have not been established. Elderly patients may be more sensitive to this medication, but generally, dosage adjustment is not necessary. This medication should not be administered to patients with moderate to severe liver impairment, and caution is required in cases of severe liver function decline. Symptoms of overdose may include hypotension and bradycardia, and immediate treatment is required if such symptoms occur. This medication should be stored out of reach of children, and transferring it to another container is not advisable as it may adversely affect quality.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a special container that protects it from light. Additionally, it should be kept at room temperature between 1°C and 30°C, in a location that is not too hot or too cold.
Oval film-coated tablet with a yellow color and a dividing line on one side
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowFimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

Fimasartan Potassium Trihydrate 132.02mg
Tablet · Prescription medication
Boryung Co., Ltd.

Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication
Boryung Pharmaceuticals Co., Ltd.

Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication
Korea Hyutex Pharmaceuticals Co., Ltd.

Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication
HanKook Hytex Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.